T1	Participants 348 387	Patients received either nicotinic acid
T2	Participants 290 346	13 patients were treated in a randomized crossover trial
T3	Participants 481 495	control period
T4	Participants 1311 1319	patients
T5	Participants 1459 1467	patients
